<DOC>
	<DOCNO>NCT01708720</DOCNO>
	<brief_summary>The purpose trial determine whether new inactivated polio vaccine base attenuated poliovirus strain safe evaluate immune response healthy adult .</brief_summary>
	<brief_title>Safety Immunogenicity New Inactivated Polio Vaccine Healthy Adults</brief_title>
	<detailed_description>The goal study assess safety immunogenicity Sabin-IPV adjuvanted Sabin-IPV produce production process set technology transfer National Institute Public Health Environment ( RIVM , formerly Netherlands Vaccine Institute ( NVI ) . - The primary objective evaluate safety ( local systemic reaction ) intramuscular injection Sabin-IPV adjuvanted Sabin-IPV healthy adult ( first human ) . - The secondary objective evaluate immunogenicity Sabin-IPV adjuvanted Sabin-IPV healthy immunize adult .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 18 49 , inclusive time enrolment good health determine outcome medical history , physical examination screening/baseline labs clinical judgment investigator Male Must receive polio vaccination OPV accord Polish National Immunization Program child base vaccination card information give subject interview investigator Preferred : number ( date ) polio vaccination know Willingness ability adhere study regimen Having sign informed consent form IPV OPV booster dose age 12 year Positive HIV , Hepatitis B Hepatitis C Known suspect allergy vaccine component History unusual severe reaction previous vaccination Known suspect disease use medication may influence immune system Known suspect immune deficiency Systemic treatment corticosteroid within one month screen Administration plasma ( include immunoglobulin ) blood product three month prior study Blood donation within one month screen Any vaccination within three month screen study last visit History neurological disorder include epilepsy febrile seizures Evidence excessive alcohol use drug use Any infectious disease time screen and/or inclusion Participation another clinical trial within three month screen Abnormal pretreatment laboratory parameter clinically relevant accord investigator Bleeding disorder usage anticoagulant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Vaccination</keyword>
	<keyword>Inactivated Poliomyelitis Vaccine</keyword>
	<keyword>Polio</keyword>
	<keyword>Sabin</keyword>
</DOC>